Thyrotropin-secreting pituitary tumors: Clinical presentation, investigation, and management

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thyrotropin-secreting tumors, often macroadenomas, comprise approximately 0.5 to 1% of pituitary neoplasms. These tumors can often be distinguished from thyroid hormone resistance by an elevated α-subunit/thyrotropin (TSH) ratio and a blunted or absent response to thyrotropin-releasing hormone. Magnetic resonance imaging demonstrating a tumor should prompt removal. Surgery alone is curative in 35% of cases, and postoperative radiation therapy is helpful. Medical therapy with long-acting somatostatin analogues reduces serum TSH, free T4, and tumor size. Abnormalities in a variety of molecular processes, cellular processes, or both have been described in pituitary tumors, including allelic deletions and loss of heterozygosity, mutations in G protein (Gsα) and the multiple endocrine neoplasia gene, overexpression of cyclin D1 and Pit-1, hypermethylation of CpG islands of the retinoblastoma gene, and abnormal expression of the p53 and p16 tumor suppressor genes. Some alterations are observed in specific subtypes of pituitary tumors. Because TSH tumors have rarely been studied, much is yet to be learned about their molecular pathogenesis. Such information will permit targeted development of more specific and effective therapies for aggressive tumors.

Original languageEnglish (US)
Pages (from-to)253-258
Number of pages6
JournalCurrent Opinion in Endocrinology and Diabetes
Volume8
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Pituitary Neoplasms
Thyrotropin
Neoplasms
Loss of Heterozygosity
Thyroid Hormone Resistance Syndrome
bcl-1 Genes
Multiple Endocrine Neoplasia
Retinoblastoma Genes
CpG Islands
Thyrotropin-Releasing Hormone
Somatostatin
Tumor Suppressor Genes
GTP-Binding Proteins
Radiotherapy
Magnetic Resonance Imaging
Gene Expression
Mutation
Therapeutics
Serum

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

@article{ddad00bfc79b46f9bd80b8d503ee9752,
title = "Thyrotropin-secreting pituitary tumors: Clinical presentation, investigation, and management",
abstract = "Thyrotropin-secreting tumors, often macroadenomas, comprise approximately 0.5 to 1{\%} of pituitary neoplasms. These tumors can often be distinguished from thyroid hormone resistance by an elevated α-subunit/thyrotropin (TSH) ratio and a blunted or absent response to thyrotropin-releasing hormone. Magnetic resonance imaging demonstrating a tumor should prompt removal. Surgery alone is curative in 35{\%} of cases, and postoperative radiation therapy is helpful. Medical therapy with long-acting somatostatin analogues reduces serum TSH, free T4, and tumor size. Abnormalities in a variety of molecular processes, cellular processes, or both have been described in pituitary tumors, including allelic deletions and loss of heterozygosity, mutations in G protein (Gsα) and the multiple endocrine neoplasia gene, overexpression of cyclin D1 and Pit-1, hypermethylation of CpG islands of the retinoblastoma gene, and abnormal expression of the p53 and p16 tumor suppressor genes. Some alterations are observed in specific subtypes of pituitary tumors. Because TSH tumors have rarely been studied, much is yet to be learned about their molecular pathogenesis. Such information will permit targeted development of more specific and effective therapies for aggressive tumors.",
author = "Smallridge, {Robert Christian}",
year = "2001",
doi = "10.1097/00060793-200110000-00005",
language = "English (US)",
volume = "8",
pages = "253--258",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Thyrotropin-secreting pituitary tumors

T2 - Clinical presentation, investigation, and management

AU - Smallridge, Robert Christian

PY - 2001

Y1 - 2001

N2 - Thyrotropin-secreting tumors, often macroadenomas, comprise approximately 0.5 to 1% of pituitary neoplasms. These tumors can often be distinguished from thyroid hormone resistance by an elevated α-subunit/thyrotropin (TSH) ratio and a blunted or absent response to thyrotropin-releasing hormone. Magnetic resonance imaging demonstrating a tumor should prompt removal. Surgery alone is curative in 35% of cases, and postoperative radiation therapy is helpful. Medical therapy with long-acting somatostatin analogues reduces serum TSH, free T4, and tumor size. Abnormalities in a variety of molecular processes, cellular processes, or both have been described in pituitary tumors, including allelic deletions and loss of heterozygosity, mutations in G protein (Gsα) and the multiple endocrine neoplasia gene, overexpression of cyclin D1 and Pit-1, hypermethylation of CpG islands of the retinoblastoma gene, and abnormal expression of the p53 and p16 tumor suppressor genes. Some alterations are observed in specific subtypes of pituitary tumors. Because TSH tumors have rarely been studied, much is yet to be learned about their molecular pathogenesis. Such information will permit targeted development of more specific and effective therapies for aggressive tumors.

AB - Thyrotropin-secreting tumors, often macroadenomas, comprise approximately 0.5 to 1% of pituitary neoplasms. These tumors can often be distinguished from thyroid hormone resistance by an elevated α-subunit/thyrotropin (TSH) ratio and a blunted or absent response to thyrotropin-releasing hormone. Magnetic resonance imaging demonstrating a tumor should prompt removal. Surgery alone is curative in 35% of cases, and postoperative radiation therapy is helpful. Medical therapy with long-acting somatostatin analogues reduces serum TSH, free T4, and tumor size. Abnormalities in a variety of molecular processes, cellular processes, or both have been described in pituitary tumors, including allelic deletions and loss of heterozygosity, mutations in G protein (Gsα) and the multiple endocrine neoplasia gene, overexpression of cyclin D1 and Pit-1, hypermethylation of CpG islands of the retinoblastoma gene, and abnormal expression of the p53 and p16 tumor suppressor genes. Some alterations are observed in specific subtypes of pituitary tumors. Because TSH tumors have rarely been studied, much is yet to be learned about their molecular pathogenesis. Such information will permit targeted development of more specific and effective therapies for aggressive tumors.

UR - http://www.scopus.com/inward/record.url?scp=0034808598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034808598&partnerID=8YFLogxK

U2 - 10.1097/00060793-200110000-00005

DO - 10.1097/00060793-200110000-00005

M3 - Article

AN - SCOPUS:0034808598

VL - 8

SP - 253

EP - 258

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 5

ER -